# Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

> **NCT06465433** · PHASE2 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 25 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Tafasitamab

## Key facts

- **NCT ID:** NCT06465433
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-08
- **Primary completion:** 2027-08-29
- **Final completion:** 2027-08-29
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06465433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06465433, "Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06465433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*